Poseida to use Janssen Centyrin technology to develop CAR therapies
Centyrins are a class of Janssen proprietary alternative scaffold molecules that can be engineered to bind to target proteins with an interface of similar size to those used
Centyrins are a class of Janssen proprietary alternative scaffold molecules that can be engineered to bind to target proteins with an interface of similar size to those used
"Immuno-oncology has emerged as a particularly promising field to create potentially curative treatment options for many cancer patients," said Victoria Richon, Vice-President and Head of Cancer Research, Discovery
Manapol is a pure, premium, 100 percent aloe vera gel extract, designed to support cell-to-cell communication.* Mannatech’s offering has a guaranteed molecular weight of more than one million
"Every year, millions of women transition into menopause causing them to experience a variety of symptoms," stated Gale Bensussen, CEO, Doctor’s Best. "We know they prefer not to
"SOMAmer molecules are a promising new class of drug entities, and we are excited to continue our work with SomaLogic to fully realize that promise," said Takayuki Shiratsuchi,
This randomized, dose-ranging trial is designed to evaluate three starting doses of ponatinib in patients with refractory, chronic-phase chronic myeloid leukemia (CP-CML) and is expected to inform the
Memantine Hydrochloride Tablets are equivalent to the branded product, Namenda, which is indicated for the treatment of moderate to severe dementia of the Alzheimer’s type. "Approximately 5.3 million
The multi-center Phase 1b trial enrolled 38 patients who were chemotherapy-naive, had unresectable MPM, had good performance status (ECOG 0 or 1), and adequate organ function. The company
The acquisition by Turing is part of a strategic effort focused on treatments for toxoplasmosis and other serious infectious diseases. The company also announced plans to invest in
The results from the multi-center, randomized Phase 2 trial showed that a single oral dose of SYM-1219 met the trial’s primary endpoint of Clinical Outcome Responder and was